MBBS, MSc, PhD
Director, Division of Molecular and Gene Therapies, Griffith Institute for Health and Medical Research
Contact details for Professor Ming Wei
Research expertise
- Cancer gene therapy
- Targeted gene delivery to solid tumour
- Lung, colon, liver cancer metastasis and microRNA studies
- Immune/gene modulation of cancer biology
- Molecular Microbiology-targetron and genetic engineering
- Anaerobic spores as gene therapy and vaccination vehicles
- Cancer real time imaging and early diagnosis
Current teaching areas
- Molecular Microbiology
Publications
- YAO Q, CAO SY, LI C, MENGENSHA A, GOOD D, KONG BH and MQ WEI. (2011) MicroRNA-21 regulates TGF-beta-induced myofibroblast differentiation by targeting PDCD4 in tumour-stroma interaction. Int J Cancer Jun 9, 128: 1783-1792. [Epub ahead of print] (ISI IMPACT FACTOR 4.794)
- ANTONY H, WIEGMANS AP, WEI MQ, KHANNA KK and MUNN AL (2011). Potential roles for prions and protein-only inheritance in cancer. Cancer and Metastasis Rev. Dec 4.
- SARAH SHIGDAR, ALISTER C WARD, ABHIJIT DE, CHAOYONG JAMES YANG, MINGQIAN WEI and WEI DUAN (2011) Clinical Applications of Aptamers and Nucleic Acid Therapeutics in Haematological Malignancies. British J Haematology (Impact Factor: 4.597, REA: A) Br J Haematol. 2011 Aug 2. doi: 10.1111
- YANG T, ZHANG B, BETTY P, WEI MQ and GOBE G. (2010). Lentiviral-mediated RNA interference for type II TGF-beta receptor inhibits renal fibrosis. J Biomed Biotech, 8: 152-69 (co-corresponding author)
- YAO Q, CAO SY, LI C, KONG BH, DAI W and MQ WEI (2010). Turn a diarrhoea toxin into a receptor-mediated therapy for a plethora of CLDN-4-overexpressing cancers. Biochem Biophy Res Comm. Jul 30; 398(3):413-9. Epub 2010 Jun 25.Y
- ANG AK, HE SM, LIU L, LIU JP, WEI MQ and ZHOU SF. (2010). Herbal interactions with anticancer drugs: mechanistic and clinical considerations. Curr Med Chem. 17(16):1635-78. (ISI IMPACT FACTOR 5.291)
- CAO SY, CRIPPS A and MQ WEI. (2009) New Strategies for Cancer Gene Therapy: Progresses and Opportunities. Clin Experim Pharmacol Physiol Aug 4. [Epub ahead of print] 37: 108-114 (ISI IMPACT FACTOR 2.196)
- XU J, LIU XS, ZHOU SF and MQ WEI. (2009) Combination of immunotherapy with anaerobic bacteria for immunogene therapy of solid tumours. Gene Therapy and Molecular Biology 13(1):36-52.
- PAREKH H, G LIU and MQ WEI. (2009). A new dawn for the use of traditional Chinese medicine in cancer therapy. Molecular Cancer 8:21 (ISI IMPACT FACTOR 5.363)
- WEI MQ, MENGESHA A, GOOD D, ANNE J (2008). Bacterial targeted tumour therapy-dawn of a new era. Cancer Lett. 259:16-27. (ISI IMPACT FACTOR 3.277)
- WEI MQ, REN A, GOOD D, ANEE J. (2008) “Trojan horse” vectors based on anaerobic bacteria for cancer gene therapy. Gene Vacc Ther 2008; 6:8 epub (Unofficial ISI IMPACT FACTOR 2.72)
- WEI MQ., ELLEM K., DUNN P., WEST MJ., B VOGELSTEIN. (2007) Facultative or obligate Anaerobic Clostridia have the potential for multimodality therapy of Solid Tumours. European Journal Cancer 43(3):490-6. (Impact Factor 4.167).